ARTICLE | Company News
De Novo, Roche drug design deal
October 16, 2001 7:00 AM UTC
De Novo ( Cambridge, U.K.) and Roche (SWX:ROCZ) will develop a computational platform to convert target structure information into therapeutic leads. The platform, Skelgen II, will be based on De Novo...